SK Bioscience has completed recruiting phase 3 participants

for the COVID-19 vaccine 4,000 people from 6 countries

Development Goals during the first half of the year

The COVID-19 vaccine GBP510, which is being developed by Korean companies, is undergoing phase 3 global clinical trials.

 

The recruitment of 4,000 people from six countries has been completed.

 

Today (18th), the government held the 26th meeting of the pan-government TF to support clinical trials of COVID-19 vaccines and treatments to discuss the progress of the development of COVID-19 vaccines in Korea.

 

The meeting was attended by Ryu Geun-hyuk, the second vice minister of the MOHW, related ministries, and private experts, and SK Bioscience President Ahn Jae-yong announced the progress of clinical trials for the COVID-19 vaccine currently under development.

 

In Korea, eight companies are currently conducting clinical trials for the COVID-19 vaccine.

 

Participating companies are SK Bioscience, EuBiologics, Geneone, Genexine, Quratis, HK inno.N, Cellid, Aijin.

 

Among them, SK Bioscience's GBP510 is being developed the fastest with its entry into phase 3 clinical trials as of August 10 last year.

 

Phase 3 clinical trials of GBP510 have recruited clinical participants from five foreign countries, including Korea, Thailand, the Philippines, Vietnam, Ukraine, and New Zealand, with a total of 3,990 subjects in five months since it began administration on August 30 last year.

 

SK Bioscience announced that it plans to complete the development of vaccines in the first half of this year through rapid sample analysis and data acquisition for vaccines under development in the future.

 

When the development of GBP510 is completed with CEPI support, it will be supplied to countries around the world through the COVAX Facility.

 

Meanwhile, the government is also conducting a pre-purchase process for 10 million doses of domestic vaccines under development by SK Bioscience.

 

Until now, the government has supported the recruitment of clinical participants, supported rapid clinical proceedings such as clinical permits through overseas missions in clinical countries, and supported rapid sample analysis led by the government for vaccine efficacy analysis through Korea National Institute of Health and the International Vaccine Institute.

 

As of the 17th, a total of 2,163 cases have been received, and 1,764 cases have been analyzed, and the sample analysis is supported to proceed quickly as soon as the sample is received.

 

In addition, a cross- and additional vaccination clinical trial under the supervision of KDCA is underway for the safe vaccination of the people after the development of domestic vaccines.

 

Second Vice Minister Ryu Geun-hyuk said, "Even when it is difficult to recruit clinical participants due to COVID-19 vaccination, we were able to complete the recruitment of clinical trial participants for domestic vaccine development smoothly thanks to the public's high interest and active cooperation.

 

After that, we will focus on support at the pan-government level so that sample analysis, approval, examination, and commercialization can proceed quickly.

 

We will support the development of various domestic vaccines and treatments, including SK Bioscience, until the end."